Scripps Clinic
16
2
2
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.3%
1 terminated/withdrawn out of 16 trials
91.7%
+5.2% vs industry average
6%
1 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Mechanisms of Dupilumab in AERD
Role: lead
Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation
Role: collaborator
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
Role: collaborator
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Role: collaborator
Postoperative Pain Control in Total Shoulder Arthroplasty
Role: lead
PRP for Rotator Cuff Tears
Role: lead
BraveNet Multi-Center Study on Integrative Medicine Treatment Approaches for Pain
Role: collaborator
Monitoring Medication Adherence in Left Ventricular Assist Device Recipients
Role: collaborator
Development of a Novel Convolution Neural Network for Arrhythmia Classification
Role: lead
FluMist in Egg Allergic Patients
Role: collaborator
Melatonin and Sleep in Preventing Delirium in the Hospital
Role: collaborator
Pilot Study of the MultiSense Patch to Record Cardiopulmonary Data During Sleep and Wake Cycles
Role: collaborator
The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)
Role: collaborator
Comparison of LDL Particle Count With Other Available Lipid Tests
Role: lead
Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma
Role: lead
Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis
Role: collaborator
All 16 trials loaded